Phathom Pharmaceuticals Inc (NASDAQ: PHAT) on Monday, soared 5.14% from the previous trading day, before settling in for the closing price of $6.23. Within the past 52 weeks, PHAT’s price has moved between $4.07 and $19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1600.29% over the past five years. The company achieved an average annual earnings per share of 24.15%. With a float of $38.63 million, this company’s outstanding shares have now reached $68.52 million.
Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Phathom Pharmaceuticals Inc is 44.53%, while institutional ownership is 60.21%. The most recent insider transaction that took place on Mar 13 ’25, was worth 44,200. In this transaction Director of this company bought 10,000 shares at a rate of $4.42, taking the stock ownership to the 85,500 shares. Before that another transaction happened on Jan 21 ’25, when Company’s CFO and CBO sold 6,583 for $6.59, making the entire transaction worth $43,371. This insider now owns 93,546 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.15% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Phathom Pharmaceuticals Inc (PHAT) is currently performing well based on its current performance indicators. A quick ratio of 4.16 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 1.65 million, a positive change from its year-to-date volume of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 94.29%. Additionally, its Average True Range was 0.59.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 16.07%, which indicates a significant decrease from 85.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 151.76% in the past 14 days, which was higher than the 105.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.90, while its 200-day Moving Average is $11.02. Nevertheless, the first resistance level for the watch stands at $6.73 in the near term. At $6.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.21. If the price goes on to break the first support level at $6.25, it is likely to go to the next support level at $5.95. Assuming the price breaks the second support level, the third support level stands at $5.77.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
Market capitalization of the company is 456.12 million based on 69,637K outstanding shares. Right now, sales total 55,250 K and income totals -334,330 K. The company made 29,660 K in profit during its latest quarter, and -74,450 K in sales during its previous quarter.
